Genesis Therapeutics, a South San Francisco, CA-based biotech company leveraging AI-technology to optimize drug discovery and development, raised $4.1m in seed funding.
The round was led by Andreessen Horowitz with participation from Felicis Ventures.
The company intends to use the funds to expand its AI-enabled drug discovery team with the active recruitment of software engineers, AI engineers and scientists.
Led by Evan Feinberg, principal founder, inventor, and CEO, Genesis aims to discover and develop innovative small molecule drug candidates for the treatment of patients with severe and debilitating disorders. The company is also actively partnering with biopharmaceutical companies worldwide to launch select novel therapies.
Dr. Feinberg co-founded the company earlier this year with software engineering leader and startup veteran Ben Sklaroff. They were joined by James Schaeffer, Ph.D. while biotech innovator Peppi Prasit, Ph.D. heads the Scientific Advisory Board. Leonard Bell, M.D., principal founder and former CEO of Alexion Pharmaceuticals, serves as Chair of the company’s Board of Directors.
Genesis Therapeutics originated out of the Stanford University lab of Vijay Pande, Ph.D., where Dr. Feinberg invented PotentialNet, the initial component of the company’s expanding portfolio of proprietary AI technologies. Genesis was subsequently founded to develop drug candidates internally and, selectively, in partnership with biopharmaceutical companies.